StocktoriaScinai Immunotherapeutics Ltd. SCNI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $1.3M | $658,000 | — | — | — |
| Gross profit | -$2.7M | -$580,000 | — | — | — |
| Operating income | -$7.5M | -$8.6M | -$9.7M | -$11.1M | -$10.9M |
| Net income | -$8.3M | $4.8M | -$6.5M | -$5.8M | -$8.2M |
| Operating cash flow | -$6.0M | -$6.3M | -$9.4M | -$7.3M | -$7.4M |
| Free cash flow | -$6.1M | -$6.3M | -$10.0M | -$8.1M | -$7.6M |
| Total assets | $11.6M | $13.4M | $17.5M | $27.1M | $32.0M |
| Shareholders' equity | $8.1M | $10.0M | -$4.6M | -$1.8M | $982,000 |
| Ratios | |||||
| Gross margin | -202.3% | -88.1% | — | — | — |
| Operating margin | -575.3% | -1312.8% | — | — | — |
| Net margin | -633.6% | 728.9% | — | — | — |
| FCF margin | -461.9% | -964.6% | — | — | — |
| Return on assets | -71.5% | 35.7% | -37.2% | -21.4% | -25.6% |
| Return on equity | -102.5% | 48.1% | 142.3% | 329.3% | -835.6% |
| Current ratio | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 |
| Revenue growth | 99.2% | — | — | — | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001611747 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.